Literature DB >> 7364937

Inhibition of hepatic binding of thyroxine by cholecystographic agents.

J V Felicetta, W L Green, W B Nelp.   

Abstract

Subsequent to studies indicating that cholecystographic agents and sulfobromophthalein (BSP) inhibit uptake of thyroxine (T(4)) by rat liver slices, the effect of such compounds on hepatic storage of T(4) in man has been examined. After intravenous administration of [(125)I]T(4) to five normal subjects, hepatic radioactivity, estimated by external gamma counting, rose to a peak in approximately 4 h and then declined in parallel with serum radioactivity. When a 6-g dose of the cholecystographic agent, tyropanoate (Bilopaque), was administered orally 3 d later, estimated hepatic extravascular radioactivity fell 50-60% within 4 h and then rose toward the pretyropanoate value. Concomitant with the fall in hepatic radioactivity, serum radioactivity rose 57-70%, as did stable T(4) levels in serum, suggesting that hormone discharged from the liver entered the serum. Both uptake of T(4) and discharge by tyropanoate were much less in two patients with liver disease. Ipodate (Oragrafin), 12 g orally in two subjects, caused much smaller changes in hepatic and serum radioactivity. However, ipodate also caused a doubling of the percent free T(4) in the serum as judged by equilibrium dialysis, and the ratio of hepatic radioactivity to free [(125)I]T(4) in serum declined markedly after ipodate, similar to the fall in hepatic:serum (125)I ratios after tyropanoate. BSP, 20 mg/kg i.v. in three subjects, caused a smaller change; the decline in hepatic T4 content averaged 19%. We conclude that these organic anions, tyropanoate, ipodate, and BSP, all can displace T(4) from the liver. The results imply a link between T(4) transport and organic anion transport, and indicate a mechanism for altering hepatic T(4) content in man that could be the site of physiologic regulation or of disease. A method is described whereby analysis of the change in hepatic and plasma radioactivity after tyropanoate could be employed to estimate hepatic T(4) content in diverse clinical circumstances.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7364937      PMCID: PMC371433          DOI: 10.1172/JCI109755

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  PROTEIN-BOUND IODINE DETERMINATION WITH STABLE END POINT.

Authors:  A LEPP; H PENA; V HOXIE; L OLINER
Journal:  Am J Clin Pathol       Date:  1965-09       Impact factor: 2.493

2.  Demonstration and some properties of cytosol-binding proteins for thyroxine and triiodothyronine in human liver.

Authors:  S Hamada; M Fukase
Journal:  J Clin Endocrinol Metab       Date:  1976-02       Impact factor: 5.958

3.  Iodothyronine metabolism in rat liver homogenates.

Authors:  M M Kaplan; R D Utiger
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

4.  Rapid redistribution of serum thyroxine during ether anesthesia.

Authors:  W Fore; P Kohler; J Wynn
Journal:  J Clin Endocrinol Metab       Date:  1966-08       Impact factor: 5.958

5.  Concentration of thyroxine in cellular and extracellular tissues of the sheep and the rate of equilibration of labeled thyroxine.

Authors:  C H Irvine
Journal:  Endocrinology       Date:  1974-04       Impact factor: 4.736

6.  The kinetics of distribution between plasma and liver of 131-I-labeled L-thyroxine in man: observations of subjects with normal and decreased serum thyroxine-binding globulin.

Authors:  R R Cavalieri; G L Searle
Journal:  J Clin Invest       Date:  1966-06       Impact factor: 14.808

7.  Free thyroxine in human serum: simplified measurement with the aid of magnesium precipitation.

Authors:  K Sterling; M A Brenner
Journal:  J Clin Invest       Date:  1966-01       Impact factor: 14.808

8.  Accumulation and rlease of thyroid hormones by the normal and diseased human liver.

Authors:  A A Zaninovich; R Volpé; R J Soto; C Ezrin
Journal:  Acta Endocrinol (Copenh)       Date:  1969-03

9.  Specific binding proteins of thyroxine and triiodothyronine in liver soluble proteins.

Authors:  S Hamada; K Torizuka; T Miyake; M Fukase
Journal:  Biochim Biophys Acta       Date:  1970-03-24

10.  Estimation of rapidly exchangeable cellular thyroxine from the plasma disappearance curves of simultaneously administered thyroxine-131-I and albumin-125-I.

Authors:  J H Oppenheimer; G Bernstein; J Hasen
Journal:  J Clin Invest       Date:  1967-05       Impact factor: 14.808

View more
  7 in total

1.  Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.

Authors:  E Martino; S Balzano; L Bartalena; A Loviselli; V Sica; L Petrini; L Grasso; M Piga; L E Braverman
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

Review 2.  Euthyroid hyperthyroxinemia.

Authors:  R Rajatanavin; L E Braverman
Journal:  J Endocrinol Invest       Date:  1983-12       Impact factor: 4.256

3.  Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves' disease.

Authors:  G Robuschi; A Manfredi; M Salvi; E Gardini; M Montermini; L d'Amato; E Borciani; L Negrotti; A Gnudi; E Roti
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

4.  Evidence that the uptake of tri-iodo-L-thyronine by human erythrocytes is carrier-mediated but not energy-dependent.

Authors:  R Docter; E P Krenning; G Bos; D F Fekkes; G Hennemann
Journal:  Biochem J       Date:  1982-10-15       Impact factor: 3.857

5.  The effects of amiodarone on thyroid function.

Authors:  N S Jaggarao; J Sheldon; E N Grundy; R Vincent; D A Chamberlain
Journal:  Postgrad Med J       Date:  1982-11       Impact factor: 2.401

6.  Peripheral serum thyroxine, triiodothyronine and reverse triiodothyronine kinetics in the low thyroxine state of acute nonthyroidal illnesses. A noncompartmental analysis.

Authors:  E M Kaptein; W J Robinson; D A Grieb; J T Nicoloff
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

Review 7.  Thyroid hormones and growth in health and disease.

Authors:  Ömer Tarım
Journal:  J Clin Res Pediatr Endocrinol       Date:  2011-06-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.